Shelly L Gray1, Zachary A Marcum1, Sascha Dublin2, Rod Walker2, Negar Golchin1,3, Dori E Rosenberg2, Erin J Bowles2, Paul Crane4, Eric B Larson2,4. 1. Department of Pharmacy, School of Pharmacy, University of Washington, Seattle. 2. Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle. 3. Comagine Health, Seattle, Washington. 4. Department of Medicine, Division of General Internal Medicine, University of Washington, Seattle.
Abstract
BACKGROUND: It is well established that individual medications that affect the central nervous system (CNS) increase falls risk in older adults. However, less is known about risks associated with taking multiple CNS-active medications. METHODS: Employing a new user design, we used data from the Adult Changes in Thought study, a prospective cohort of community-dwelling people aged 65 and older without dementia. We created a time-varying composite measure of CNS-active medication exposure from electronic pharmacy fill data and categorized into mutually exclusive categories: current (within prior 30 days), recent (31-90 days), past (91-365 days), or nonuse (no exposure in prior year). We calculated standardized daily dose and identified new initiation. Cox proportional hazards models examined the associations between exposures and the outcome of fall-related injury identified from health plan electronic databases. RESULTS: Two thousand five hundred ninety-five people had 624 fall-related injuries over 15,531 person-years of follow-up. Relative to nonuse, fall-related injury risk was significantly greater for current use of CNS-active medication (hazard ratio [HR] = 1.95; 95% CI = 1.57-2.42), but not for recent or past use. Among current users, increased risk was noted with all doses. Risk was increased for new initiation compared with no current use (HR = 2.81; 95% CI = 2.09-3.78). Post hoc analyses revealed that risk was especially elevated with new initiation of opioids. CONCLUSIONS: We found that current use, especially new initiation, of CNS-active medications was associated with fall-related injury in community-dwelling older adults. Increased risk was noted with all dose categories. Risk was particularly increased with new initiation of opioids.
BACKGROUND: It is well established that individual medications that affect the central nervous system (CNS) increase falls risk in older adults. However, less is known about risks associated with taking multiple CNS-active medications. METHODS: Employing a new user design, we used data from the Adult Changes in Thought study, a prospective cohort of community-dwelling people aged 65 and older without dementia. We created a time-varying composite measure of CNS-active medication exposure from electronic pharmacy fill data and categorized into mutually exclusive categories: current (within prior 30 days), recent (31-90 days), past (91-365 days), or nonuse (no exposure in prior year). We calculated standardized daily dose and identified new initiation. Cox proportional hazards models examined the associations between exposures and the outcome of fall-related injury identified from health plan electronic databases. RESULTS: Two thousand five hundred ninety-five people had 624 fall-related injuries over 15,531 person-years of follow-up. Relative to nonuse, fall-related injury risk was significantly greater for current use of CNS-active medication (hazard ratio [HR] = 1.95; 95% CI = 1.57-2.42), but not for recent or past use. Among current users, increased risk was noted with all doses. Risk was increased for new initiation compared with no current use (HR = 2.81; 95% CI = 2.09-3.78). Post hoc analyses revealed that risk was especially elevated with new initiation of opioids. CONCLUSIONS: We found that current use, especially new initiation, of CNS-active medications was associated with fall-related injury in community-dwelling older adults. Increased risk was noted with all dose categories. Risk was particularly increased with new initiation of opioids.
Authors: Mary E Tinetti; Ling Han; David S H Lee; Gail J McAvay; Peter Peduzzi; Cary P Gross; Bingqing Zhou; Haiqun Lin Journal: JAMA Intern Med Date: 2014-04 Impact factor: 21.873
Authors: Stephanie Studenski; Subashan Perera; Kushang Patel; Caterina Rosano; Kimberly Faulkner; Marco Inzitari; Jennifer Brach; Julie Chandler; Peggy Cawthon; Elizabeth Barrett Connor; Michael Nevitt; Marjolein Visser; Stephen Kritchevsky; Stefania Badinelli; Tamara Harris; Anne B Newman; Jane Cauley; Luigi Ferrucci; Jack Guralnik Journal: JAMA Date: 2011-01-05 Impact factor: 56.272
Authors: Shelly L Gray; Melissa L Anderson; Sascha Dublin; Joseph T Hanlon; Rebecca Hubbard; Rod Walker; Onchee Yu; Paul K Crane; Eric B Larson Journal: JAMA Intern Med Date: 2015-03 Impact factor: 21.873
Authors: Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist Journal: Breast Cancer Res Treat Date: 2014-02-21 Impact factor: 4.872
Authors: Suzanne G Leveille; Richard N Jones; Dan K Kiely; Jeffrey M Hausdorff; Robert H Shmerling; Jack M Guralnik; Douglas P Kiel; Lewis A Lipsitz; Jonathan F Bean Journal: JAMA Date: 2009-11-25 Impact factor: 56.272
Authors: Laura A Hart; Rod Walker; Elizabeth A Phelan; Zachary A Marcum; Naomi R M Schwartz; Paul K Crane; Eric B Larson; Shelly L Gray Journal: J Am Geriatr Soc Date: 2021-10-19 Impact factor: 5.562
Authors: Anthony V Herrera; Linda Wastila; Jessica P Brown; Hegang Chen; Steven R Gambert; Jennifer S Albrecht Journal: J Head Trauma Rehabil Date: 2021 Sep-Oct 01 Impact factor: 2.710
Authors: Donovan T Maust; Julie Strominger; H Myra Kim; Kenneth M Langa; Julie P W Bynum; Chiang-Hua Chang; Helen C Kales; Kara Zivin; Erica Solway; Steven C Marcus Journal: JAMA Date: 2021-03-09 Impact factor: 56.272
Authors: Joshua D Niznik; Brendan J Collins; Lori T Armistead; Claire K Larson; Casey J Kelley; Tamera D Hughes; Kimberly A Sanders; Rebecca Carlson; Stefanie P Ferreri Journal: Res Social Adm Pharm Date: 2021-07-16